Viking Therapeutics, Inc.

Eli Lilly and Company

Novo Nordisk A/S

Side effects of Viking's obesity pill upset investors

Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?

Wegovy is first-in-class approved for the treatment of liver disease, but its exclusivity is threatened by US-based Eli Lilly

Novo Nordisk shares rise after approval of Wegovy to treat liver disease

Cisco Systems, Inc.

Equinox Gold Corp.

Walmart Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: quotes are driven by cautious optimism

Block, Inc.

Rocket Lab Corporation

Tesla, Inc.

Morning in New York: investors need a breather


In contrast, the securities of Eli Lilly's main competitor, Danish Novo Nordisk, rose in price by almost 7%


Eli Lilly has disappointed with the outcome of a weight loss pill trial. Shares are down 15%


Over the past year - from July 2024 to August 2025 - Novo Nordisk's stock, <a href="https://oninvest.com/issuers/novo-b-co">has lost</a> nearly 70% in value. That's a fantastic collapse for a company that makes sought-after diabetes and weight-loss drugs&nbsp; and is showing good revenue and profit growth. What happened to Novo Nordisk and how much of this investor reaction is justified?

The Novo Nordisk case: how the creator of Ozempic lost leadership in the market it created

Apple Inc.

DoorDash, Inc.

Morning in New York: foreign trade agenda remains in focus

After two worsening of the annual forecast and the change of the head of the company, the market is cautious


Sales of the drug Wegovy increased by 67%. Will this convince Novo Nordisk investors?


Since the beginning of the year, Novo Nordisk's market value has fallen 50 times more than that of its main competitor, Eli Lilly

UBS no longer advises buying shares in the maker of Ozempic. Is it inferior to a competitor?

Palantir Technologies Inc.

The Walt Disney Company

U.S. stocks retreated from record highs late last week when fresh employment data showed that the U.S. labor market was not as robust as thought. Wall Street is expecting a relatively quiet macroeconomic agenda this week with no significant releases scheduled, <a href="https://finance.yahoo.com/news/job-market-concerns-take-center-stage-as-earnings-season-rolls-on-what-to-watch-this-week-113608612.html#:~:text=Markets%20will%20be%20greeted%20with%20a%20quieter%20week%20of%20economic%20news%20with%20no%20major%20releases%20anticipated.">write</a> Yahoo Finance. Investors' attention may be drawn to the publication of ISM's U.S. services sector business activity index for July, <a href="https://www.wsj.com/economy/week-ahead-for-fx-bonds-u-s-ism-services-data-in-focus-boe-expected-to-cut-rates-dcdd3318?mod=central-banking_news_article_pos5">accounts</a> The Wall Street Journal. The previously reported data on activity in the manufacturing sector came in below forecasts - along with weak employment figures, this "heightens concerns about a slowdown in the economy," <a href="https://www.wsj.com/economy/week-ahead-for-fx-bonds-u-s-ism-services-data-in-focus-boe-expected-to-cut-rates-dcdd3318?mod=central-banking_news_article_pos5#:~:text=This%20data%20follows%20below%2Dforecast%20ISM%20data%20on%20the%20manufacturing%20sector%2C%20which%2C%20alongside%20the%20weak%20jobs%20figures%2C%20%E2%80%9Camplifies%20concerns%20about%20economic%20slowdown%2C%E2%80%9D%20said%20Aaron%20Hill%2C%20analyst%20at%20FP%20Markets%2C%20in%20a%20note.">the WSJ quoted FP Markets analyst Aaron Hill as saying</a>.

Disney, Palantir and Novo Nordisk reports: what investors need to know this week

Pfizer Inc.

The US President sent letters to 17 pharmaceutical market leaders

Pharma stocks plummet after Trump's demand for price cuts. Should we be worried?

The developer of Ozempic is under pressure from both aggressive competition with Eli Lilly and the abundance of copies of its drugs on the U.S. market

#: 26